New: NCI-funded clinical trial search
Mednet Logo
SpecialtiesMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

With what agents can you replace PPIs if they cause thrombocytopenia?

1
1 Answers

Mednet Member
Mednet Member
Hematology · Indiana University

The incidence of PPI-induced thrombocytopenia is very low - and really only reported in case reports. I would suggest ensuring the low platelet count is really from the PPI (in some cases may be reasonable to re-challenge the patient), and not from a more common reason. In a recent case report on La...

What would be your preferred second line treatment for a frail elderly patient progressing on Rd?

3
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Chicago

It will largely depend on the degree of frailty. Many of the myeloma therapeutics are well tolerated, even among older adults or those with comorbidities. Factors such as the time spent coming to clinic or to the infusion center matter as well. It is useful to understand the baseline cytogenetic abn...

Would you offer a complement inhibitor to a minimally symptomatic PNH patient with mild non-transfusion dependent hemolytic anemia?

1 Answers

Mednet Member
Mednet Member
Hematology · Mount Sinai School of Medicine

The context would determine whether this patient should receive complement inhibitor. The first consideration is whether the patient has concurrent aplastic anemia or bone marrow failure. Often, patients with aplastic anemia have a small PNH clone that is not clinically significant and does not caus...

In which platelet function disorders would you consider use of Novoseven as opposed to platelet transfusion?

1 Answers

Mednet Member
Mednet Member
Hematology · Mayo Clinic

There are now two recombinant activated factor VII (rFVIIa) available in the US. Trade names are NovoSeven RT and SEVENFACT. NovoSeven RT is US FDA approved for use in Glanzmann thrombasthenia. There are case reports of its efficacy in off label use for other inherited platelet function defects. SEV...

Under what circumstances would you consider anticoagulation in a young female patient with persistently elevated factor XI activity?

1 Answers

Mednet Member
Mednet Member
Hematology · Mount Sinai

First, get a baseline D-dimer to see how procoagulant she is at that point. If elevated, long travel on plane, pre-op and post-op for 2 months - consider short-term anticoagulation. If past thrombosis - give lifelong anticoagulation. If pregnant - follow D-dimer; if it goes up, anticoagulate.